Computationally generated cardiac biomarkers for risk stratification after acute coronary syndrome

Science Translational Medicine

Volumn 3, Issue 102, 2011, Pages

  Syed, Zeeshan ^a   Stultz, Collin M ^b,c   Scirica, Benjamin M ^b,d   Guttag, John V ^c  

^a UNIVERSITY OF MICHIGAN   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; RANOLAZINE; PLACEBO;

ACUTE CORONARY SYNDROME; ADULT; AGED; ARTICLE; CARDIOVASCULAR RISK; CAUSE OF DEATH; CLINICAL ARTICLE; CONTROLLED STUDY; DECELERATION; DISEASE MARKER; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAPHY MONITORING; FEMALE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART RATE VARIABILITY; HUMAN; MALE; MATHEMATICAL COMPUTING; MATHEMATICAL MODEL; NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; POPULATION RISK; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; RISK ASSESSMENT; T WAVE; BIOLOGICAL MODEL; BIOLOGY; CLINICAL TRIAL (TOPIC); ECHOGRAPHY; HEART INFARCTION; HEART MUSCLE; HEART RATE; HEART STROKE VOLUME; METABOLISM; METHODOLOGY; MIDDLE AGED; MULTIVARIATE ANALYSIS; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; RISK FACTOR;

ACUTE CORONARY SYNDROME; AGED; BIOLOGICAL MARKERS; CLINICAL TRIALS AS TOPIC; COMPUTATIONAL BIOLOGY; FEMALE; HEART RATE; HUMANS; MALE; MIDDLE AGED; MODELS, CARDIOVASCULAR; MULTIVARIATE ANALYSIS; MYOCARDIAL INFARCTION; MYOCARDIUM; PLACEBOS; RISK FACTORS; STROKE VOLUME;

EID: 80053235012     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.3002557     Document Type: Article

References (39)

1. D. Lloyd-Jones, R. J. Adams, T. M. Brown, M. Carnethon, S. Dai, G. De Simone, T. B. Ferguson, E. Ford, K. Furie, C. Gillespie, A. Go, K. Greenlund, N. Haase, S. Hailpern, P. M. Ho, V. Howard, B. Kissela, S. Kittner, D. Lackland, L. Lisabeth, A. Marelli, M. M. McDermott, J. Meigs, D. Mozaffarian, M. Mussolino, G. Nichol, V. L. Roger, W. Rosamond, R. Sacco, P. Sorlie, T. Thom, S. Wasserthiel-Smoller, N. D. Wong, J. Wylie-Rosett; American Heart Association Statistics Committee and Stroke Statistics Subcommittee, Heart disease and stroke statistics - 2010 update: A report from the American Heart Association. Circulation 121, e46-e215 (2010).
2. K. S. Reddy, Cardiovascular disease in non-Western countries. N. Engl. J. Med. 350, 2438-2440 (2004).
3. E. C. Keeley, J. A. Boura, C. L. Grines, Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: A quantitative review of 23 randomised trials. Lancet 361, 13-20 (2003).
4. S. R. Mehta, C. P. Cannon, K. A. Fox, L. Wallentin, W. E. Boden, R. Spacek, P. Widimsky, P. A. McCullough, D. Hunt, E. Braunwald, S. Yusuf, Routine vs selective invasive strategies in patients with acute coronary syndromes: A collaborative meta-analysis of randomized trials. JAMA 293, 2908-2917 (2005).
5. K. P. Alexander, L. K. Newby, C. P. Cannon, P. W. Armstrong, W. B. Gibler, M. W. Rich, F. van de Werf, H. D. White, W. D. Weaver, M. D. Naylor, J. M. Gore, H. M. Krumholz, E. M. Ohman; American Heart Association Council on Clinical Cardiology; Society of Geriatric Cardiology, Acute coronary care in the elderly, part I: Non-ST-segment-elevation acute coronary syndromes: A scientific statement for healthcare professionals fromthe American Heart Association Council on Clinical Cardiology: In collaboration with the Society of Geriatric Cardiology. Circulation 115, 2549-2569 (2007).
6. C. P. Cannon, W. S. Weintraub, L. A. Demopoulos, R. Vicari, M. J. Frey, N. Lakkis, F. J. Neumann, D. H. Robertson, P. T. DeLucca, P. M. DiBattiste, C. M. Gibson, E. Braunwald; TACTICS (Treat Angina with Aggrastat and Determine Cost of Therapy with an Invasive or Conservative Strategy)-Thrombolysis in Myocardial Infarction 18 Investigators, Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban. N. Engl. J. Med. 344, 1879-1887 (2001).
7. B. M. Scirica, Acute coronary syndrome: Emerging tools for diagnosis and risk assessment. J. Am. Coll. Cardiol. 55, 1403-1415 (2010).
8. J. L. Anderson, C. D. Adams, E. M. Antman, C. R. Bridges, R. M. Califf, D. E. Casey Jr., W. E. Chavey II, F. M. Fesmire, J. S. Hochman, T. N. Levin, A. M. Lincoff, E. D. Peterson, P. Theroux, N. K. Wenger, R. S. Wright, S. C. Smith Jr., A. K. Jacobs, C. D. Adams, J. L. Anderson, E. M. Antman, J. L. Halperin, S. A. Hunt, H. M. Krumholz, F. G. Kushner, B. W. Lytle, R. Nishimura, J. P. Ornato, R. L. Page, B. Riegel; American College of Cardiology; American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction); American College of Emergency Physicians; Society for Cardiovascular Angiography and Interventions; Society of Thoracic Surgeons; American Association of Cardiovascular and Pulmonary Rehabilitation; Society for Academic Emergency Medicine, ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction) developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. J. Am. Coll. Cardiol. 50, e1-e157 (2007).
9. J. Searle, O. Danne, C. Müller, M. Mockel, Biomarkers in acute coronary syndrome and percutaneous coronary intervention. Minerva Cardioangiol. 59, 203-223 (2011).
10. D. Tousoulis, A. M. Kampoli, E. Stefanadi, C. Antoniades, G. Siasos, A. G. Papavassiliou, C. Stefanadis, New biochemical markers in acute coronary syndromes. Curr. Med. Chem. 15, 1288-1296 (2008).
11. R. S. Vasan, M. G. Larson, E. J. Benjamin, J. C. Evans, C. K. Reiss, D. Levy, Congestive heart failure in subjects with normal versus reduced left ventricular ejection fraction: Prevalence and mortality in a population-based cohort. J. Am. Coll. Cardiol. 33, 1948-1955 (1999).
12. A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. The Antiarrhythmics versus Implantable Defibrillators (AVID) Investigators. N. Engl. J. Med. 337, 1576-1583 (1997).
13. A. E. Buxton, K. L. Lee, J. D. Fisher, M. E. Josephson, E. N. Prystowsky, G. Hafley, A randomized study of the prevention of sudden death in patients with coronary artery disease. Multicenter Unsustained Tachycardia Trial Investigators. N. Engl. J. Med. 341, 1882-1890 (1999).
14. A. E. Epstein, J. P. DiMarco, K. A. Ellenbogen, N. A. Estes III, R. A. Freedman, L. S. Gettes, A. M. Gillinov, G. Gregoratos, S. C. Hammill, D. L. Hayes, M. A. Hlatky, L. K. Newby, R. L. Page, M. H. Schoenfeld, M. J. Silka, L. W. Stevenson, M. O. Sweeney, S. C. Smith Jr., A. K. Jacobs, C. D. Adams, J. L. Anderson, C. E. Buller, M. A. Creager, S. M. Ettinger, D. P. Faxon, J. L. Halperin, L. F. Hiratzka, S. A. Hunt, H. M. Krumholz, F. G. Kushner, B. W. Lytle, R. A. Nishimura, J. P. Ornato, B. Riegel, L. G. Tarkington, C. W. Yancy; American College of Cardiology/American Heart Association Task Force on PracticeGuidelines (Writing Committee to Revise the ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices); American Association for Thoracic Surgery; Society of Thoracic Surgeons, ACC/AHA/HRS 2008 Guidelines forDevice-Based Therapy of Cardiac RhythmAbnormalities:A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices): Developed in collaboration with the American Association for Thoracic Surgery and Society of Thoracic Surgeons. Circulation 117, e350-e408 (2008).
15. D. B. Mark, C. L. Nelson, K. J. Anstrom, S. M. Al-Khatib, A. A. Tsiatis, P. A. Cowper, N. E. Clapp-Channing, L. Davidson-Ray, J. E. Poole, G. Johnson, J. Anderson, K. L. Lee, G. H. Bardy; SCD-HeFT Investigators, Cost-effectiveness of defibrillator therapy or amiodarone in chronic stable heart failure: Results from the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT). Circulation 114, 135-142 (2006).
16. J. J. Goldberger, M. E. Cain, S. H. Hohnloser, A. H. Kadish, B. P. Knight, M. S. Lauer, B. J. Maron, R. L. Page, R. S. Passman, D. Siscovick, W. G. Stevenson, D. P. Zipes; American Heart Association; American College of Cardiology Foundation; Heart Rhythm Society, American Heart Association/American College of Cardiology Foundation/Heart Rhythm Society scientific statement on noninvasive risk stratification techniques for identifying patients at risk for sudden cardiac death: A scientific statement from the American Heart Association Council on Clinical Cardiology Committee on Electrocardiography and Arrhythmias and Council on Epidemiology and Prevention. Circulation 118, 1497-1518 (2008).
17. Z. Syed, B. M. Scirica, S. Mohanavelu, P. Sung, E. L. Michelson, C. P. Cannon, P. H. Stone, C. M. Stultz, J. V. Guttag, Relation of death within 90 days of non-ST-elevation acute coronary syndromes to variability in electrocardiographic morphology. Am. J. Cardiol. 103, 307-311 (2009).
18. Z. Syed, J. V. Guttag, Identifying patients at risk of major adverse cardiovascular events using symbolic mismatch. Proceedings of the Neural Information Processing Systems, 2010.
19. C. C. Chia, Z. Syed, Computationally generated cardiac biomarkers: Heart rate patterns to predict death following coronary attacks. Proceedings of the 11th SIAM International Conference on Data Mining, SDM 2011, Mesa, AZ, 28 to 30 April 2011.
20. E. M. Antman, M. Cohen, P. J. Bernink, C. H. McCabe, T. Horacek, G. Papuchis, B. Mautner, R. Corbalan, D. Radley, E. Braunwald, The TIMI risk score for unstable angina/non-ST elevation MI: A method for prognostication and therapeutic decision making. JAMA 284, 835-842 (2000).
21. V. N. Vapnik, The Nature of Statistical Learning Theory (Springer, New York, 1995).
22. W. S. Noble, What is a support vector machine? Nat. Biotechnol. 24, 1565-1567 (2006).
23. D. A. Morrow, B. M. Scirica, E. Karwatowska-Prokopczuk, S. A. Murphy, A. Budaj, S. Varshavsky, A. A. Wolff, A. Skene, C. H. McCabe, E. Braunwald; MERLIN-TIMI 36 Trial Investigators, Effects of ranolazine on recurrent cardiovascular events in patients with non-ST-elevation acute coronary syndromes: The MERLIN-TIMI 36 randomized trial. JAMA 297, 1775-1783 (2007).
24. D. A. Morrow, B. M. Scirica, E. Karwatowska-Prokopczuk, A. Skene, C. H. McCabe, E. Braunwald; MERLIN-TIMI 36 Investigators, Evaluation of a novel anti-ischemic agent in acute coronary syndromes: Design and rationale for the Metabolic Efficiency with Ranolazine for Less Ischemia in Non-ST-elevation acute coronary syndromes (MERLIN)-TIMI 36 trial. Am. Heart J. 151, 1186.e1-1186.e9 (2006).
25. P. S. Hamilton, W. J. Tompkins, Quantitative investigation of QRS detection rules using the MIT/BIH arrhythmia database. IEEE Trans. Biomed. Eng. 33, 1157-1165 (1986).
26. W. Zong, G. B. Moody, D. Jiang, A robust open-source algorithm to detect onset and duration of QRS complexes. Comput. Cardiol. 737-740 (2003).
27. C. S. Myers, L. R. Rabiner, A comparative study of several dynamic time-warping algorithms for connected-word recognition. Bell Syst. Tech. J. 60, 1389-1409 (1981).
28. Z. Syed, P. Sung, B. M. Scirica, D. A. Morrow, C. M. Stultz, J. V. Guttag, Spectral energy of ECG morphologic differences to predict death. Cardiovasc. Eng. 9, 18-26 (2009).
29. H. P. van Dongen, E. Olofsen, J. H. vanHartevelt, E. W. Kruyt, A procedure of multiple period searching in unequally spaced time-series with the Lomb-Scargle method. Biol. Rhythm Res. 30, 149-177 (1999).
30. G. D. Clifford, L. Tarassenko, Quantifying errors in spectral estimates of HRV due to beat replacement and resampling. IEEE Trans. Biomed. Eng. 52, 630-638 (2005).
31. P. Barthel, R. Schneider, A. Bauer, K. Ulm, C. Schmitt, A. Schömig, G. Schmidt, Risk stratification after acute myocardial infarction by heart rate turbulence. Circulation 108, 1221-1226 (2003).
32. Z. Syed, J. Guttag, C. Stultz, Clustering and symbolic analysis of cardiovascular signals: Discovery and visualization of medically relevant patterns in long-term data using limited prior knowledge. EURASIP J. Adv. Sig. Pr. 2007, 1-16 (2007).
33. Y. H. Chen, E. K. Garcia, M. R. Gupta, A. Rahimi, L. Cazzanti, Similarity-based classification: Concepts and algorithms. J. Mach. Learn. Res. 10, 747-776 (2009).
34. J. Lin, E. Keogh, L. Wei, S. Lonardi, Experiencing SAX: A novel symbolic representation of time series. Data Min. Knowl. Disc. 15, 107-144 (2007).
35. D. R. Cox, Regression models and life-tables. J. Roy. Stat. Soc. B 34, 187-220 (1972).
36. F. E. Harrell Jr., K. L. Lee, R. M. Califf, D. B. Pryor, R. A. Rosati, Regression modelling strategies for improved prognostic prediction. Stat. Med. 3, 143-152 (1984).
37. F. E. Harrell Jr., K. L. Lee, D. B. Mark, Multivariable prognostic models: Issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat. Med. 15, 361-387 (1996).
38. M. J. Pencina, R. B. D'Agostino Sr., R. B. D'Agostino Jr., R. S. Vasan, Evaluating the added predictive ability of a new marker: From area under the ROC curve to reclassification and beyond. Stat. Med. 27, 157-172 (2008).
39. Acknowledgments: We thank the TIMI Study Group at the Brigham and Women's Hospital (Boston, MA). Funding: Supported by the National Science Foundation, the American Heart Association, the Center for Integration of Medicine and Innovative Technology, Quanta Computer, and the Harvard-MIT Division of Health Sciences and Technology. The TIMI-DISPERSE2 trial was supported by AstraZeneca LLC. The MERLIN-TIMI36 trial was supported by CV Therapeutics (now Gilead Sciences). Author contributions: All authors participated in the study design, interpretation of reported experiments and results, and writing of the manuscript. Z.S. was responsible for writing the software routines for measuring the biomarkers. Z.S. and B.M.S. carried out the statistical analyses. Competing interests: B.M.S. has received research support via Brigham and Women's Hospital from Gilead Sciences and served as a paid consultant. The other authors declare that they have no competing interests. The Massachusetts Institute of Technology has submitted a patent application for the use of the MV analysis with Z.S., C.M.S., and J.V.G. listed as inventors.